ECTRIMS 2019

Showing 1 posts of 1 posts found.

Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis

September 12, 2019
Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …

The Gateway to Local Adoption Series

Latest content